GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough
GRAIL, Inc. shares soared to record highs this week after the company announced a strategic collaboration with Samsung. On October 16, GRAIL revealed a binding agreement in which Samsung C&T and Samsung Electronics will invest $110 million into GRAIL at $70.05 per sharets2.tech. In return, Samsung C&T gains exclusive rights to distribute GRAIL’s Galleri multi-cancer early detection blood test in South Korea, with plans to expand to Japan and Singaporets2.tech. Samsung Electronics will explore technology tie-ups, integrating its digital health platforms and AI with GRAIL’s cancer-detection technologytradingview.comprnewswire.com. Investors cheered the deal as a major validation of GRAIL’s prospects. GRAL stock jumped ~13–14% on October 16, hitting a new 52-week peak around $85–$86 per sharets2.tech. Reuters noted the stock “rose 13% to $85.35, hitting a record high” intraday on the announcementts2.tech. This rally added roughly $300 million to GRAIL’s market capitalization, lifting it to about $2.7 billionts2.tech. By contrast, the broader market slipped about 0.6% that dayfinviz.com, underscoring how GRAIL’s news bucked the market trend. The Samsung investment price represented a 15% premium to GRAIL’s prior close, setting a benchmark valuation for the companyts2.tech. Including this surge, GRAL has now climbed over 300% year-to-date, rising more than fourfold in 2025tradingview.com.
